| Diabetes Mellitus, Non-Insulin-Dependent
Jentadueto vs Trulicity
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jentadueto vs Trulicity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrulicity has a higher rate of injection site reactions vs Jentadueto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trulicity but not Jentadueto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jentadueto
Trulicity
At A Glance
Oral
Twice daily
DPP-4 inhibitor / biguanide
SC injection
Once weekly
GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Individualized dosing orally twice daily with meals; starting at 2.5 mg linagliptin/500 mg metformin HCl twice daily for metformin-naive patients, maximum 2.5 mg linagliptin/1,000 mg metformin HCl twice daily; contraindicated if eGFR <30 mL/min/1.73 m2; initiation not recommended if eGFR 30-45 mL/min/1.73 m2.
Diabetes Mellitus, Non-Insulin-Dependent (Adults) Starting dose 0.75 mg SC once weekly; may increase to 1.5 mg after 4 weeks; further increases in 1.5 mg increments after at least 4 weeks on current dose; maximum 4.5 mg SC once weekly.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric, >=10 years) Starting dose 0.75 mg SC once weekly; if additional glycemic control needed, increase to maximum 1.5 mg SC once weekly after at least 4 weeks.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to linagliptin, metformin, or any excipient in JENTADUETO
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to dulaglutide or any product component
Adverse Reactions
Most common (>=5%) Nasopharyngitis, diarrhea (combination); diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache (metformin initiation)
Serious Lactic acidosis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, rash, cholestatic/hepatocellular/mixed liver injury
Most common (>=5%) Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia, fatigue
Serious Thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury, severe gastrointestinal reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration
Postmarketing Hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, cholestasis, elevated liver enzymes, hepatitis, anaphylactic reactions, angioedema, dysgeusia, dysesthesia, acute renal failure, alopecia
Pharmacology
Linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin release and reducing glucagon secretion; metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Dulaglutide is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37) that activates the GLP-1 receptor in pancreatic beta cells, stimulating glucose-dependent insulin release, decreasing glucagon secretion, and slowing gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jentadueto
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
Trulicity
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
UnitedHealthcare
Jentadueto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Trulicity
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Jentadueto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Trulicity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jentadueto.
$25/momo
Trulicity Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JentaduetoView full Jentadueto profile
TrulicityView full Trulicity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.